Year None202420232022202120202019201820172016 Date Latest Press Release April 21, 2022 Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5 April 18, 2022 Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments March 17, 2022 Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study March 16, 2022 Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022 March 10, 2022 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update February 24, 2022 Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10 January 6, 2022 Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones January 3, 2022 Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference December 21, 2021 Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection December 15, 2021 Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
